How Is Acute Myeloid Leukemia (AML) Treatment Changing?

Acute myeloid leukemia, or AML, has long been one of the most challenging cancers to treat. Over the past decade, research advances in molecular testing, targeted therapies, and more personalized treatment approaches have brought a remarkable wave of progress for patients with AML.

Once largely treated with intensive chemotherapy and prolonged hospital stays, AML care is now more tailored to the specific characteristics of a patient’s leukemia, including genetic mutations that can influence how the disease behaves and what types of treatment may be the most effective.

Dr. Manish Shah, Chief of the Solid Tumor Program and Director of Gastrointestinal Oncology at Weill Cornell Medicine, recently spoke with Dr. Gail Roboz, Director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine, about cancer care advances and the new treatment strategies that are changing outcomes for patients and shaping the future of AML care.

What Is Acute Myeloid Leukemia?

Acute myeloid leukemia is the most common type of acute leukemia in adults. It is a form of blood cancer, and a relatively rare disease overall compared to more common forms of cancer such as breast or colon cancer. AML begins in the bone marrow, the soft tissue inside bones responsible for producing blood cells. The bone marrow is the organ responsible for being the body’s blood-making factory, the epicenter that creates red blood cells to carry oxygen throughout the body, white blood cells to fight infections, and platelets to help people clot and stop bleeding when injured.

“The bone marrow isn’t taught as being a vital organ like the heart, lungs, or brain,” Dr. Roboz says. “But in order for the heart or a brain or lungs to function properly, they need the blood supply which comes from the bone marrow.”

In AML, leukemic cells take over the bone marrow and crowd out normal blood production. As these abnormal cells accumulate, the body becomes less able to produce the healthy blood cells it needs to function. “The production of normal blood cells disappears,” explains Dr. Roboz. “That loss is what makes the disease so dangerous and fast-moving.” As additional context and history for the name itself, Dr. Roboz explains that acute myeloid leukemia was named “acute” in the first place because without treatment, it can quickly become life-threatening within weeks.

What Are the Symptoms of AML and How is it Diagnosed?

Because AML interferes with normal blood cell production, many of its symptoms are related to low blood counts. Common symptoms include persistent fatigue, frequent or recurring infections, fever, unusual bruising or bleeding, bone or joint pain, or bleeding under the skin.

Symptoms can develop over a relatively short period of time, often days to weeks, although each person’s individual experience may vary. Some patients may not even have symptoms, and AML is discovered incidentally during blood work for something else. Because these symptoms can have many root causes, they don’t automatically indicate leukemia, but persistent or unexplained symptoms should be evaluated by a medical professional.

Diagnosing AML involves several types of blood and bone marrow testing. A complete blood count (CBC) may reveal abnormal numbers of red blood cells, white blood cells, or platelets and a blood smear can also help identify abnormal blood cells.

If AML is suspected, doctors typically then perform a bone marrow aspiration and biopsy. These procedures collect samples of bone marrow so they can be examined under the microscope and with additional sophisticated testing to determine if leukemia is present.

Further testing can also help identify the specific type of AML and provides information that can guide treatment decisions. For example, molecular or genetic testing helps identify specific gene mutations that may influence the behavior of the leukemia or provide targets for treatment. These tests are particularly important because AML is not one single disease. Understanding the subtype and genetic characteristics of an individual’s leukemia is increasingly important to selecting the right treatment.

How Is AML Treated?

AML treatment has two major goals. The first is to get the disease into remission. Induction therapy is the initial phase of treatment to clear the bad cells from the body and restore normal blood production. This is most often accomplished by using chemotherapy. When a patient achieves remission, blood counts improve and the bone marrow no longer shows signs of active leukemia. However, remission does not necessarily mean that every cancerous cell has been eliminated.

The next goal is designed to reduce the risk of relapse and return of the disease. Depending on the patient, this may involve a bone marrow or stem cell transplant or additional chemotherapy.

“Getting a patient into remission is only the first step,” Dr. Roboz explains. “Once you’re in remission, there is the decision of what’s the best way to keep the marrow working and achieve a cure.”

A stem cell transplant, or bone marrow transplant, is an important treatment option for some people with AML. However, a transplant is not appropriate for everyone. The decision depends on several factors including the characteristics of the leukemia, the patient’s response to initial treatment, and their overall health.

Age alone does not automatically rule out a transplant. Improvements in both leukemia treatment and transplant techniques have made transplantation possible for some older adults who may not previously have been considered candidates.

The Molecular Revolution in AML Care

One of the biggest shifts in AML care has been the move toward molecular testing and the ability to identify specific genetic mutations within leukemia cells. “We used to just throw rocks at cancer cells and hope that they died,” notes Dr. Roboz. “Chemotherapy was a hammer, and cancer cells were nails.” Today, tools like next-generation sequencing identify specific mutations, such as FLT3 or NPM1, that help predict how a disease will behave and which treatments may work best.

Not every mutation has a corresponding targeted treatment, but identifying these mutations helps physicians better understand the disease and personalize care. Molecular testing is also now able to detect cancer down to one in a million leukemia cells, thus enabling physicians to identify signs of relapse prior to any symptoms.

Dr. Roboz notes that prior to 2017, hardly any AML therapies had been FDA-approved in the previous 30 years and now, 14 different therapies have been approved since that time. “It’s been an absolute tsunami of good things happening in the field,” she says. While there is still more work to be done, the progress in the field has been exponential in the last decade.

Dr. Shah connects this to a broader shift in cancer care. “Just like in solid tumors, the idea is that we’re not grouping big diseases together. We’re actually splitting them apart and then refining our treatments to those individual diseases.”

A Model of Hope: The APL Story

One subtype of AML, acute promyelocytic leukemia (APL), offers a powerful example of what targeted treatment can achieve. Once among the deadliest forms of leukemia, treatment advances have transformed the outlook for APL. A major breakthrough came with all-trans retinoic acid (ATRA), a vitamin A derivative that helps leukemia cells mature into more normal cells. This combined with arsenic trioxide and deep molecular monitoring gave patients a more targeted treatment approach without traditional intensive chemotherapy.

“We took the worst subtype of the disease, got targeted agents, got rid of the heavy-duty chemotherapy, molecularly monitored it until the disease was gone, and we turned tragedy into cure,” explains Dr. Roboz. It is the model researchers now hope to replicate across other subtypes.

New All-Oral Treatment Options for Older Patients

For decades, effective AML treatment required intensive chemotherapy that many older patients simply could not tolerate, despite the median age of diagnosis being 67. Many patients in their 70s and 80s were not healthy enough to receive this chemotherapy regimen so their options were more limited. However, newer treatment combinations are changing the landscape for these patients and other patients who aren’t able to tolerative intensive chemotherapy.

Dr. Roboz and colleagues recently published a landmark study in The New England Journal of Medicine on an all-oral regimen combining oral decitabine with cedazuridine and venetoclax.

Hypomethylating agents like decitabine work by affecting how genes are regulated in cells, which helps to disrupt the abnormal processes that allow leukemia cells to grow. Cedazuridine helps prevent decitabine from being broken down in the digestive system, allowing it to be absorbed when taken as a pill. Venetoclax targets a protein called BCL-2 which the leukemia cells depend on to survive.

“Leukemic cells have a force field around themselves called BCL-2. Venetoclax actually takes down that force field and allows leukemic cells to then get killed,” she explains.

The all-oral approach allows many patients to receive ongoing treatment at home rather than spending weeks in the hospital. “This combination therapy gave patients who were older or otherwise unable to tolerative intensive chemotherapy an effective therapy option, “Dr. Shah says.  

About 50% of patients were able to achieve remission in this study, which led to the U.S. Food and Drug Administration (FDA) approving this regimen for the treatment of newly diagnosed AML in adults 75 years or older or those who are unable to receive intensive chemotherapy.

This FDA approval opens up the treatment options available to patients. Although this therapy is exciting, there are still potential side effects even when taking pills. Potential side effects include low blood counts, fatigue, nausea, diarrhea, and an increased risk of infection.

The Art of Tailoring AML Treatment

One of the most important themes to emerge in AML care is how individualized this treatment must be. Dosing and timing are adjusted continually based on how each patient responds. Dr. Roboz contrasts it with following the instructions on a boxed cake recipe. “This isn’t a simple recipe or formula even though the ingredients are the same,” she emphasizes. “The nuances of tailoring the dose and the schedule of oral decitabine, cedazuridine, and the venetoclax is incredibly important.”

This monitoring and adjusting is especially important after remission. During initial treatment, the goal is to eliminate as many leukemia cells as possible. But once a patient is in remission, doctors must balance controlling any remaining leukemia cells against protecting healthy blood cell production. Too much treatment can cause blood counts to fall dangerously low, increasing the risk of infections, bleeding, and other complications. Too little treatment may not adequately suppress the leukemia.

Dr. Shah notes how this reflects something essential about medicine itself. “It actually gets to the art of medicine. It takes human thought and time and skill to make these adjustments.”

Looking Toward the Future

Although many newer AML regimens were initially developed for older adults, researchers are also investigating whether these approaches may benefit younger patients. A trial called PARADIGM is exploring hypomethylating agents combined with venetoclax against standard treatment approaches. Certain subgroups, such as those with difficult-to-treat TP53 mutations, may do better avoiding harsh chemotherapy altogether. “Just because you can handle it doesn’t mean it’s better for you,” cautions Dr. Roboz.

However, some patients may still benefit from traditional intensive chemotherapy, and research is ongoing to better understand which individual patients may benefit from different treatment strategies.

Clinical trials continue to play a critical role in improving AML treatment. “Participating in a clinical trial may provide access to promising therapies that are not yet widely available,” Dr. Shah says. “Future patients also can benefit from trial participation now.”

Real-world data also helps researchers understand how treatments work for patients with different types of AML, other medical conditions, or circumstances that might have excluded them from a trial. The continuation of research is helping physicians to refine treatment and improve care for a broader range of patients.

Ultimately, Dr. Roboz’s vision circles back to the APL success story. “I want the APL story for all of AML,” she notes. “Get in with therapy that is more targeted, wipe out the cells in a super strategic way, and then measure it so that I can tell the patient there are no more leukemic cells.’”

For patients and families facing an AML diagnosis, these advances offer important reasons for hope. Treatment decisions remain complex and highly individualized, but the growing rate of new therapies, improved monitoring techniques, and ongoing clinical research are changing what’s possible for people with AML.

Learn more about recent advances in AML on the CancerCast podcast where Drs. Shah and Roboz dive further into the specifics of this new all-oral regimen and other recent improvements in the treatment of AML on Apple Podcasts, Spotify, YouTube, or the Weill Cornell Medicine website.